Jaguar Health Q3 2024 GAAP EPS $(1.05) Beats $(2.37) Estimate, Sales $3.11M Miss $3.94M Estimate
Jaguar Health Q3 2024 GAAP EPS $(1.05) Beats $(2.37) Estimate, Sales $3.11M Miss $3.94M Estimate
jaguar health 2024財季的按照通用會計準則每股收益爲$(1.05)，超過了$(2.37)的預期，銷售額爲311萬美元，低於394萬美元的預期
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(2.37) by 55.7 percent. The company reported quarterly sales of $3.11 million which missed the analyst consensus estimate of $3.94 million by 21.05 percent. This is a 10.52 percent increase over sales of $2.81 million the same period last year.
Jaguar Health (納斯達克:JAGX) 報告了每股虧損 $(1.05)，超出了分析師共識預期的每股 $(2.37) 達到 55.7%。公司報告的季度銷售額爲 $311萬，未能達到分析師共識預期的 $394萬，差距爲 21.05%。與去年同期的 $281萬銷售額相比，增長了 10.52%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間